From Mumbai to the markets that matter.
M Care was founded in Mumbai in 2002 to solve a single problem: the reliable, regulated-market supply of essential medicines from India to the hospitals, importers and tender desks that cannot afford a stock-out. Twenty-plus years on, that is still the only problem we work on.
An export house with a documentation obsession.
We are a privately held pharmaceutical export house with a head office in Mumbai, commercial offices in London and Dubai, and logistics partners on six continents. Our founding team combined hospital-side procurement experience with international freight expertise, a blend that still shapes how we operate.
We're not a broker. We don't buy speculative stock. Every line we ship starts with a purchase order, runs through a direct manufacturer relationship, and ends with a signature on a delivery note. That's the short version of why importers, hospital pharmacies and tender desks trust us with repeat business for years at a time.
We sell from Mumbai into 45+ markets across ten regions: the UK, Germany and France in Europe; UAE, Saudi Arabia, Kuwait, Oman, Qatar and Bahrain across the GCC; Jordan, Iraq, Egypt, Morocco and Tunisia across the wider MENA and Maghreb; Nigeria, Kenya, Ghana, South Africa, Ethiopia, Tanzania, Uganda, Rwanda, Mauritius, Côte d'Ivoire, Senegal, Cameroon, DR Congo and Mozambique across the African continent; Sri Lanka, Nepal and Bangladesh in South Asia; the Philippines, Vietnam, Thailand and Malaysia in ASEAN; Kazakhstan and Uzbekistan in Central Asia; Azerbaijan in the Caucasus; Ukraine across Eastern Europe through donor and ProZorro channels; and Brazil, Mexico, Colombia, Peru, Chile and the Dominican Republic in Latin America and the Caribbean. India, where our head office sits, is deliberately not one of those markets. We are a pharmaceutical exporter, not an Indian domestic supplier.
The desk you're actually talking to.
Family-run, professionally staffed. Two decades of continuity at the top means every supply problem you raise has been seen before — and every quote you get is signed off by a named principal, not a rotating junior.
Shailendra Bhatt
Managing Director · Founder
Founded M Care in 2002 after a decade in pharmaceutical wholesale and institutional supply. Sets the commercial strategy, owns the principal-manufacturer relationships, and signs off on every tender response. Twenty-plus years of continuity with the WHO-GMP partners that still supply us today.
Dr. Rajat Bhatt
Director, Operations
Runs day-to-day export operations across the Mumbai, London and Dubai desks. Oversees QA, regulatory affairs, dispatch and cold-chain. The named contact most hospital buyers and tender desks end up working with when an order runs longer than a single PO.
Three offices, one operating model.
Every order is run end-to-end by a named team, never handed across desks, never lost in a call-centre queue.
London, United Kingdom
Commercial office for UK, European and Commonwealth accounts. Regulatory liaison with MHRA and EMA. Primary contact for named-patient and unlicensed-imports enquiries.
Regulatory · Commercial · Tender response
Dubai, United Arab Emirates
Regional hub for GCC and East-African accounts. Direct relationships with SFDA, MOHAP, DHA and the Gulf Health Council. Bonded warehousing for JAFZA and DAFZA shipments.
GCC liaison · Bonded stock · East Africa
Mumbai, India
Operational and sourcing headquarters. QA audits, vendor qualification, dispatch, and artwork control. In-house regulatory-affairs team covers CTD/eCTD dossier authoring and variation management.
Sourcing · QA · Dispatch · Dossiers
The documentation defines the deal.
Our entire value proposition rests on documentation that survives an audit. Every manufacturing partner is qualified against a standard protocol, WHO-GMP as the baseline, EU-GMP or US-FDA where the destination market demands it. Every batch ships with a full certificate of analysis, method of analysis, certificate of origin, and pack insert matched to the destination label.
- Quality standards: WHO-GMP is the baseline; EU-GMP / US-FDA / PIC/S partners for regulated markets.
- Certifications: ISO 9001:2015 for the export operation. ISO 13485 partnerships for medical devices.
- Regulatory reach: CTD/eCTD dossiers for MHRA, EMA, SFDA, DHA, MOHAP, NAFDAC, PPB, TFDA, SAHPRA, and the Gulf Health Council.
- Artwork control: destination-market labelling reviewed and locked before shipment, with change-control discipline on every revision.
- Cold-chain: audited 2–8°C and −25°C lanes with validated temperature loggers on every unit; excursion protocol insured and written into the PO.
A business defined as much by what we turn down.
Pharmaceutical exports is a trade where the sharp edges are obvious. Ours is a simple list.
No grey-market stock
Every batch is traceable to a single manufacturing site, with a paper chain that would hold up in any regulator's audit. We don't resell parallel-imported or secondary-market stock.
No counterfeits, no compromises
Every partner site is physically audited by our QA team before first order and re-audited on a defined cycle. Non-compliant partners are removed from the roster, no exceptions, ever.
No surprise pricing
Your quote includes insurance, freight, dossier, and artwork. No invoice bloat after the shipment ships. What you confirm on day one is what you pay on day forty.
If you supply hospitals, importers or tender desks, we should talk.
Send us the molecule, the volume, and the market. We'll reply with a price, a timeline and a regulatory status, inside one working day, from a named person.
Start an enquiry →